Mike Wood, LeapFrog founder, dies by physician-assisted suicide due to Alzheimer's diagnosis
Wood passed away earlier this month in Switzerland, where physician-assisted suicide is legal, his brother confirmed. He was reportedly "surrounded by family" at the time of his death.
According to family statements, Wood chose to end his life before the Alzheimer's disease progressed significantly, maintaining his desire for dignity and control in the face of a devastating illness.
Wood, a California resident, launched LeapFrog in the mid-1990s after noticing his three-year-old son's struggles with reading.
The company quickly rose to prominence with the 1999 release of the LeapPad, a groundbreaking educational device that became the best-selling toy during the 2000 holiday season.
Wood stepped away from the company in 2004 but remained a respected figure in the educational technology space. LeapFrog Enterprises paid tribute to its founder in a statement posted on Instagram.
"We are saddened by the loss of LeapFrog founder, Mike Wood," the company said. "His passion to find a new way to help his child learn led to something remarkable... We loved working with Mike and are honoured to continue what he started."
Wood is survived by his son and three grandchildren.
His death marks the passing of a visionary entrepreneur whose innovations in early childhood education technology have impacted millions of children worldwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
29-04-2025
- Express Tribune
Mike Wood, LeapFrog founder, dies by physician-assisted suicide due to Alzheimer's diagnosis
Mike Wood, founder of the educational toy company LeapFrog Enterprises, has died by physician-assisted suicide following a diagnosis of Alzheimer's disease. He was 72. Wood passed away earlier this month in Switzerland, where physician-assisted suicide is legal, his brother confirmed. He was reportedly "surrounded by family" at the time of his death. According to family statements, Wood chose to end his life before the Alzheimer's disease progressed significantly, maintaining his desire for dignity and control in the face of a devastating illness. Wood, a California resident, launched LeapFrog in the mid-1990s after noticing his three-year-old son's struggles with reading. The company quickly rose to prominence with the 1999 release of the LeapPad, a groundbreaking educational device that became the best-selling toy during the 2000 holiday season. Wood stepped away from the company in 2004 but remained a respected figure in the educational technology space. LeapFrog Enterprises paid tribute to its founder in a statement posted on Instagram. "We are saddened by the loss of LeapFrog founder, Mike Wood," the company said. "His passion to find a new way to help his child learn led to something remarkable... We loved working with Mike and are honoured to continue what he started." Wood is survived by his son and three grandchildren. His death marks the passing of a visionary entrepreneur whose innovations in early childhood education technology have impacted millions of children worldwide.
Express Tribune
28-04-2025
- Express Tribune
Is marriage linked to dementia? New study explains
Listen to article Contrary to popular belief, marriage may be linked to a higher risk of dementia in older age in the United States, according to a new study by researchers at Florida State University, US. The study, led by Selin Karakose and colleagues, tracked over 24,000 Americans with an average age of 72 for up to 18 years. Participants were divided into four groups: married, widowed, divorced, and never married. 'Unmarried individuals may have a lower risk of dementia compared to married adults,' the study's authors wrote. After adjusting for age and gender, the findings revealed that those who had never married were 40% less likely to develop dementia than married individuals. Widowed participants had a 27% lower risk, and divorced individuals had a 34% lower risk. The results challenge previous research suggesting marriage offers protective benefits against cognitive decline. Earlier studies linked marriage to stronger immune systems, reduced stress, and greater social support—all factors thought to guard against dementia. However, the new research, published in the journal Alzheimer's & Dementia, turns this assumption on its head. 'Contrary to expectations and challenging the commonly held belief that marriage is protective against cognitive decline and dementia, this study found that married older adults exhibited a higher risk of dementia compared to those never married, divorced, and widowed,' an expert commented. The study does not offer a definitive explanation for the trend. Researchers suggest possible factors, such as smaller social networks among married individuals, increased caregiving-related stress, or delayed dementia diagnosis in unmarried people. The authors cautioned that the study does not imply all married individuals are destined to develop dementia. Rather, it highlights that the relationship between marriage and cognitive health is complex and warrants further research. Experts advise individuals to focus on building strong, supportive relationships and maintaining a healthy, low-stress lifestyle, regardless of marital status, to promote better brain health in later life.
Express Tribune
17-04-2025
- Express Tribune
Lilly's oral weight-loss pill shows promise amid pharma shakeup: TIME
Listen to article In a detailed feature by TIME Magazine, pharmaceutical giant Eli Lilly has unveiled promising early results from clinical trials of its experimental oral drug orforglipron, a GLP-1-based treatment for diabetes and weight loss. The development marks a potentially transformative moment for both the company and the obesity-treatment landscape. The data, presented during a critical meeting at Lilly's Indianapolis headquarters on April 15, showed that orforglipron lowered blood sugar levels and aided weight loss without serious side effects like liver toxicity—an issue that recently led Pfizer to abandon its own oral drug in the same category. Orforglipron's results were comparable to Lilly's injectable blockbuster tirzepatide (Mounjaro). If approved by the FDA, orforglipron could become the first oral GLP-1 drug for weight loss on the market. Unlike competing drugs, it requires no dietary restrictions or timing constraints and is easier and cheaper to manufacture and distribute—especially in areas where injectables are impractical. Lilly's CEO David Ricks and Chief Scientific Officer Dr Dan Skovronsky credited the company's agile approach, culture shift, and high-speed innovation for the drug's progress. The pill was licensed from Japan's Chugai in 2018 and developed 30–40% faster than industry averages, according to Ricks. The company is investing heavily in domestic production, anticipating a surge in demand. Trials are ongoing to evaluate orforglipron's effectiveness in non-diabetic obesity and other conditions like hypertension. If successful, the drug could dramatically expand access to obesity treatments and redefine the market. This effort is part of Lilly's broader push to break industry norms, including direct-to-consumer models like Lilly Direct, which bypass intermediaries to lower costs. With additional breakthroughs like the Alzheimer's drug Kisunla, Lilly is now the world's most valuable pharma firm—and possibly the first on track to a $1 trillion valuation.
